TETRAVI Expanded Access Program

AVAILABLE

NCT07104591

Sponsor: Baylor College of Medicine

Summary

This Expanded Access Program (EAP) allows qualified physicians within Texas to obtain access to multivirus-specific cytotoxic T lymphocytes (VSTs) developed under Baylor College of Medicine's TETRAVI program (NCT04013802) for the treatment of persistent or recurrent infections with EBV, CMV, adenovirus, or BK virus in pediatric patients being treated in Texas who have received allogeneic stem cell transplants and have no other suitable therapeutic options.

Official title: Expanded Access Use of Multivirus-Specific Cytotoxic T-Lymphocytes for Pediatric Patients With EBV, CMV, Adenovirus, or BK Virus Infections Post Allogeneic Stem Cell Transplant

Key Details

Gender

All

Age Range

Any - 17 Years

Study Type

EXPANDED_ACCESS

Enrollment

Not specified

Start Date

Not specified

Completion Date

Not specified

Last Updated

2026-09-15

Healthy Volunteers

Not specified

Conditions

Epstein-Barr Virus Infection Cytomegalovirus Infections Adenovirus Infection BK Virus Infection JC Virus Infection Viral Infections Post-Transplant Post-Allogeneic Stem Cell Transplant Complications

Interventions

BIOLOGICAL

HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes)

Banked, partially HLA-matched virus-specific T cells (VSTs) directed against EBV, CMV, adenovirus, and BK virus.

Clinical Research Directory